公开(公告)号：US20230194547A1

公开(公告)日：2023-06-22

申请号：US18045037

申请日：2022-10-07

Applicant: Hoffmann-La Roche Inc.

Inventor： Anna-Lena BOLENDER ,  Martina DUSCHMALE ,  Lisa EBELER ,  Johannes FRAIDLING ,  Thomas KRAFT

IPC: G01N33/68 ,  G01N33/58 ,  G01N33/50

CPC classification number: G01N33/6854 ,  G01N33/582 ,  G01N33/5061 ,  G01N2333/70535

Abstract: Herein is reported a method for determining non-specific clearance of an antibody comprising the steps of incubating the antibody, which is conjugated to a pH-sensitive fluorescent dye, with primary human endothelial cells, and determining the fluorescence intensity of the primary human endothelial cells, whereby an increase of the fluorescence intensity of the primary human endothelial cells above background level is indicative for non-specific clearance of the antibody.

公开(公告)号：US20220025046A1

公开(公告)日：2022-01-27

申请号：US17218948

申请日：2021-03-31

Applicant: Hoffmann-La Roche Inc.

Inventor： Maria AMANN ,  Juergen Peter BACHL ,  Alexander BUJOTZEK ,  Carina CANTRILL ,  Harald DUERR ,  Janine FAIGLE ,  Sabine IMHOF-JUNG ,  Christian KLEIN ,  Thomas KRAFT ,  Estelle MARRER-BERGER ,  Ekkehard MOESSNER ,  Laurene POUSSE ,  Petra RUEGER ,  Johannes SAM ,  Roland STAACK ,  Dietrich TUERCK ,  Pablo UMANA ,  Joerg ZIELONKA

IPC: C07K16/28 ,  C07K16/46 ,  A61P35/00 ,  C07K16/30 ,  A61K45/06

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

公开(公告)号：US20240117049A1

公开(公告)日：2024-04-11

申请号：US18457729

申请日：2023-08-29

Applicant: Hoffmann-La Roche Inc.

Inventor： Maria AMANN ,  Juergen Peter BACHL ,  Alexander BUJOTZEK ,  Carina CANTRILL ,  Harald DUERR ,  Janine FAIGLE ,  Sabine IMHOF-JUNG ,  Christian KLEIN ,  Thomas KRAFT ,  Estelle MARRER-BERGER ,  Ekkehard MOESSNER ,  Laurene POUSSE ,  Petra RUEGER ,  Johannes SAM ,  Roland STAACK ,  Dietrich TUERCK ,  Pablo UMANA ,  Joerg ZIELONKA

IPC: C07K16/28 ,  A61K45/06 ,  A61P35/00 ,  C07K16/30 ,  C07K16/46 ,  C12N15/63

CPC classification number: C07K16/2809 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2878 ,  C07K16/30 ,  C07K16/468 ,  C12N15/63 ,  A61K2039/505

Abstract: The invention relates to novel bispecific antigen binding molecules, comprising at least two antigen binding domains capable of specific binding to OX40 and a particular antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.

公开(公告)号：US20220073593A1

公开(公告)日：2022-03-10

申请号：US17237426

申请日：2021-04-22

Applicant: Hoffmann-La Roche Inc.

Inventor： Thomas EMRICH ,  Hubert KETTENBERGER ,  Thomas KRAFT ,  Wolfgang RICHTER ,  Tilman SCHLOTHAUER

IPC: C07K16/00 ,  B01D15/38

Abstract: Herein is reported a method for providing a modified antibody with improved in vivo half-live, comprising the modification of the Fc-region of the antibody by introducing one or more mutations that change the binding of the Fc-region to human FcRn until the (relative) retention time of the modified antibody in an FcRn affinity chromatography is increased for more than 1 minute but not more than 5 minutes compared to the parent antibody.